Kangchen Pharmaceutical: Wholly owned subsidiary Kangchen Hong Kong subscribes to 38,439,500 shares of Series E preferred stock newly issued by UroGen Cayman for 150 million yuan.

Kangchen Pharmaceuticals announced that its wholly-owned subsidiary Kangchen Hong Kong signed a Share Subscription Agreement with YouRui Cayman and its subsidiaries. Kangchen Hong Kong plans to participate in YouRui Cayman's E-round financing by subscribing to 38,439,500 shares of E-round preferred stock at a price of 150 million RMB. The funds raised in this round of financing will be used for YouRui Cayman's business expansion, capital expenditures, operating expenses, and to support its application for listing of innovative drugs, as well as to meet other operational funding needs.